Close Menu

Breaking News

The Medicare Administrative Contractor will cover ctDNA tests if the patient has a personal history of colorectal cancer.

Biocartis noted that it has suspended its partnership with Exact Sciences to develop the Idylla IVD Oncotype Dx Breast Recurrence Score test project due to the pandemic.

The firm also announced that all of its coronavirus tests would return additional results for Influenzas A and B by the end of September.

The nationwide study will enroll prostate cancer patients who do and don't meet current guidelines and assess how access to genetic information impacts their care. 

The point-of-care test provides results in 15 minutes and can be used for both symptomatic and asymptomatic patients.

Color Genomics' kit is designed for the unmonitored self-collection of nasal swab specimens for SARS-CoV-2 testing.

IVDs in the future will require certification in England, Scotland, and Wales, while companies will still be able to sell tests in Northern Ireland under existing EU regulations.

The funding will be used to start a new trial to assess the benefits of repeat population testing, expand existing trials, and increase PCR-based testing capacity.

The study, conducted in Italy, also found a high rate of false negatives with RT-PCR-based nasal swab tests performed early in a patient's recovery.

Some of the firms will receive money to speed up test development, while others will use the funds to expand their testing and manufacturing capacity.

Created by BloodPAC members, the resource may serve as a set of generic analytical protocols to help define industry standards for developing liquid biopsy tests.

Google Cloud said that the augmented reality microscope would enable access to artificial intelligence models that can help military doctors with cancer detection.

For the second quarter, sales for its clinical applications jumped nearly 14 percent, while industrial applications fell 7 percent year over year.

The tests are designed to detect antibodies against SARS-CoV-2 in order to help identify individuals with an adaptive immune response to the virus.

Todos also announced a $23.8 million sales agreement this week with an unnamed Wisconsin laboratory covering testing equipment and supplies.

The Australian molecular diagnostics firm had stockholders' equity in excess of $2.5 million as of Aug. 28, in compliance with the Nasdaq listing rule.

The tests are designed to detect viral RNA in individual respiratory specimens, while BayCare's tests can be used with pooled samples.

DeCode Genetics researchers found patients' antibody titers increased in the two months following diagnosis, then stabilized.

State agencies will no longer use Quest for testing following its failure to report to the state results from roughly 75,000 SARS-CoV-2 tests in a timely manner.

Of the 28 companies in the index, 12 firms saw their stock prices increase, while 16 firms' share prices decreased. 

The joint venture will establish CLIA labs within SG Blocks' shipping container-based structures, with an initial focus on SARS-CoV-2 testing.

The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, enabling appropriate treatment options.

The two tests, both of which use RT-PCR technology to detect multiple viral targets, may be performed only by their respective developers.

T2 Bio's T2SARS-CoV-2 Panel detects SARS-CoV-2 within two hours using a nasopharyngeal swab sample and runs on the firm's T2Dx instrument.

The firm said that in addition to home use, its test for SARS-CoV-2 antibodies could be used in clinics and hospital emergency rooms.